Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/9/2025

Osteoporosis Management in Postmenopausal Women

Understanding the T-score Classification

  • The American College of Radiology states that a T-score of -1.7 falls within the osteopenia range, indicating low bone mass but not osteoporosis, with the patient having lower bone density than the young adult reference population but not yet reaching the threshold for osteoporosis diagnosis (T-score ≤ -2.5) 2, 3
  • The World Health Organization classification system is used to define osteopenia and osteoporosis, with T-scores between -1.0 and -2.5 indicating osteopenia 2, 1

Silent Fracture Risk Assessment

  • The Journal of the American College of Radiology recommends vertebral fracture assessment (VFA) for patients with T-scores less than -1.0 who are postmenopausal women age 70 years or older, have historical height loss >4 cm, have self-reported prior vertebral fracture, or are on chronic glucocorticoid therapy 4
  • Approximately 50% of fragility fractures occur in postmenopausal women with T-scores greater than -2.5, making fracture risk assessment critical beyond BMD alone 4

Immediate Non-Pharmacological Management

  • The American Family Physician recommends a weight-bearing exercise regimen to maintain and potentially improve bone density 1
  • The American College of Obstetricians and Gynecologists suggests calcium supplementation to achieve >1000 mg/day total intake (dietary plus supplements) and vitamin D supplementation 800-1000 IU daily 3, 1

Fracture Risk Calculation Required

  • The National Osteoporosis Foundation recommends calculating the 10-year fracture risk using FRAX or similar algorithm, which incorporates clinical risk factors beyond BMD alone, including age, prior fracture history, parental hip fracture history, current smoking, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis causes, and alcohol consumption 1
  • Pharmacologic treatment should be considered if FRAX shows 10-year risk of major osteoporotic fracture ≥20% or hip fracture risk ≥3%, even with a T-score in the osteopenic range 3

Appropriate Monitoring Interval

  • The American College of Radiology recommends repeat DEXA scanning in 1-2 years for patients with osteopenia at increased risk, to assess for progression 1, 5
  • The International Society for Clinical Densitometry states that repeat measurements should be performed on the same DXA scanner at the same facility using identical positioning and technique, as vendor differences prohibit direct comparison unless cross-calibration has been performed 4, 1

When Pharmacologic Treatment Would Be Indicated

  • The American College of Obstetricians and Gynecologists recommends immediate treatment if VFA reveals a vertebral fracture, or if FRAX shows high fracture risk as defined above 3, 1
  • The National Osteoporosis Foundation suggests first-line therapy with bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly) and alternative therapy with denosumab 60 mg subcutaneously every 6 months if bisphosphonates cannot be tolerated 1

REFERENCES

1

updated practice guideline for dual-energy x-ray absorptiometry (dxa). [LINK]

European Journal of Nuclear Medicine and Molecular Imaging, 2025

3

Management of Osteopenia [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025